Thereson S.p.A., a Vimercate, Italy-based company which has developed an innovative and clinically effective medical device technology for the treatment of diabetic foot ulcers, completed a €1m financing round.
Backers included existing investor 360 Capital Partners and a number of private investors, including managers and entrepreneurs.
The company, which has now raised €4,5m in total, intends to use the funds to initiate the commercial sales of DIAPASON™, hire sales and marketing specialists, and conduct further clinical research.
Founded in 2011 and led by Claudio Simmi (CEO) and Enrico Fermi (Scientific & Technical Manager), Thereson has developed the THERESON TMR™ technology, which consists of exposing patients to Pulsating Electro-Magnetic Fields (PEMF) at specific (IP protected) frequencies. The therapy, suitable for home care, is delivered through simple procedures lasting about 25 minutes, twice per day, for a period of 4 – 8 weeks.
DIAPASON™ is a medical device aimed to the treatment of Diabetic Foot ulcers, which has recently obtained the CE mark. It is composed of:
– a console which generates the electrical signals and includes patient interface, display and commands for self-treatment at home.
– a set of two “emitters” connected to the console that convert the electrical signals into pulsating magnetic fields: one called “total body” for systemic treatment and one called “local therapy” for treatment of the ulcer area.